US · NXGL
NEXGEL, Inc.
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Langhorne, PA 19047
- Website
- nexgel.com
Price · as of 2024-12-31
$0.58
Market cap 12.25M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $37.61 | +6,372.21% |
| Intrinsic Value(DCF) | $199.60 | +34,248.65% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $0.00 | $19.53 | |||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $1.93 | $43.28 | $5.14 | $0.00 | $0.00 |
| 2022 | $1.44 | $23.81 | $13.33 | $0.00 | $0.00 |
| 2023 | $2.81 | $38.65 | $6,113.46 | $0.00 | $0.00 |
| 2024 | $2.95 | $37.61 | $26,427.53 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates NEXGEL, Inc.'s (NXGL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $37.61
- Current price
- $0.58
- AI upside
- +6,372.21%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$199.60
+34,248.65% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NXGL | NEXGEL, Inc. | $0.58 | 12.25M | +6,372% | +34,249% | — | — | -5.85 | 3.34 | 2.21 | -6.97 | — | 5.03 | 31.63% | -40.91% | -37.76% | -62.78% | -61.44% | -31.34% | 0.49 | -43.88 | 2.07 | 1.11 | -0.35 | -1071.00% | 11247.00% | 961.00% | -22.44% | -1.57 | -74.51% | 0.00% | 0.00% | 0.00% | -5.69 | -4.69 | 2.33 | 0.07 |
| ENLV | Enlivex Therapeutics Ltd. | $1.15 | 27.95M | — | — | — | — | -1.63 | 1.03 | — | -0.09 | — | 1.03 | 0.00% | — | — | -55.95% | -720.93% | -46.54% | 0.02 | -1195.08 | 6.84 | 6.56 | 0.19 | -5321.00% | — | -4482.00% | -53.71% | -3.42 | -608.40% | 0.00% | 0.00% | 12.23% | -0.09 | -0.10 | — | -3.74 |
| FEMY | Femasys Inc. | $0.57 | 16.78M | +4,489% | +5% | — | — | -1.78 | 14.49 | 20.50 | -2.29 | — | 14.92 | 66.55% | -1091.75% | -1155.03% | -182.18% | -369.29% | -93.61% | 3.23 | -11.09 | 0.93 | 0.46 | -0.24 | -968.00% | 5197.00% | 7686.00% | -60.49% | -2.27 | -419.54% | 0.00% | 0.00% | 0.00% | -2.10 | -1.85 | 22.95 | -16.97 |
| GDTC | CytoMed Therapeutics Limi… | $1.08 | 12.67M | +4,473% | +13% | — | +965% | -16.97 | 4.76 | 601.35 | -15.62 | — | 4.81 | 100.72% | -5049.84% | -3621.15% | -24.43% | -98.92% | -22.01% | 0.05 | -172.79 | 9.89 | 8.22 | 1.84 | -4483.00% | -8210.00% | 1064.00% | -9.62% | -4.47 | -113.37% | 0.00% | 0.00% | 0.00% | -10.65 | -9.29 | 537.89 | 22.44 |
| HBIO | Harvard Bioscience, Inc. | $0.61 | 27.44M | +5,740% | -46% | — | +242% | -2.88 | 0.56 | 0.38 | -51.62 | -1.16 | -8.67 | 58.18% | -6.60% | -13.18% | -18.19% | -5.77% | -9.40% | 0.70 | -1.94 | 0.82 | 0.35 | -27.40 | 24783.00% | -1614.00% | -11556.00% | -5.11% | 0.03 | -1.69% | 0.00% | 0.00% | 0.00% | -12.25 | -41.74 | 0.81 | -0.92 |
| IINN | Inspira Technologies Oxy … | $0.58 | 13.97M | — | — | — | — | -1.42 | 3.64 | — | -1121.82 | — | 3.64 | 0.00% | — | — | -219.74% | 7.39% | -127.19% | 0.58 | — | 2.02 | 1.71 | 234.68 | -9994.00% | — | -426.00% | -60.68% | -2.78 | -6254.43% | 0.00% | 0.00% | 0.00% | 1104.79 | -1.31 | — | -8.52 |
| MTVA | MetaVia Inc. | $1.51 | 3.32M | — | — | — | — | -0.44 | 1.52 | — | 0.13 | -0.97 | 1.52 | 0.00% | — | — | -224.18% | 426.89% | -141.35% | 0.02 | — | 1.94 | 1.94 | 0.55 | 4472.00% | — | 12784.00% | -205.58% | -2.99 | 366.27% | 0.00% | 0.00% | 0.00% | 0.13 | 0.16 | — | -16.10 |
| NXL | Nexalin Technology, Inc. | $0.47 | 8.77M | +5,717% | +102% | — | — | -2.88 | 5.97 | 130.00 | -2.38 | -9.08 | 6.42 | 78.31% | -4596.14% | -4508.73% | -221.05% | -3380.55% | -193.70% | 0.00 | — | 7.25 | 6.39 | 0.07 | 3175.00% | 5235.00% | -1.00% | -17.98% | -7.21 | -1719.51% | 0.00% | 0.00% | 0.00% | -2.38 | -4.68 | 109.37 | -9.04 |
| POCI | Precision Optics Corporat… | $4.28 | 33.04M | +286% | +2,105% | — | — | -5.25 | 2.48 | 1.59 | -5.73 | -7.15 | 9.48 | 17.83% | -29.08% | -30.28% | -51.78% | -43.34% | -31.50% | 0.17 | -24.45 | 1.64 | 0.99 | -0.05 | 7347.00% | -7.00% | 2680.00% | -12.44% | -0.58 | -29.47% | 0.00% | 0.00% | 9.11% | -5.52 | -8.11 | 1.60 | -1.34 |
About NEXGEL, Inc.
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was founded in 1997 and is based in Langhorne, Pennsylvania.
- CEO
- Adam R. Levy
- Employees
- 19
- Beta
- 0.59
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($199.60 ÷ $0.58) − 1 = +34,248.65% (DCF, example).